DVF has put her signature style and fashion for flair on two new ophthalmic frames. The latest release showcases a rich and vibrant acetate frame front with translucent temples featuring her signature metal foil logo. The DVF5085 (photo) is a must have for today’s busy modern woman. To further compliment the collection is DVF8054, a timeless semi-rimless frame with unique and innovative temples creating a chic colour bloc look.
Diane von Furstenberg is distributed by Marchon: www.marchon.com
The French luxury goods group LVMH is preparing to acquire a 10% stake in Italy-based Marcolin Eyewear, in order to ensure better control over production.
Relatives of the LVMH group told Bloomberg and Reuter that the intentions of LVMH are expected to made known in the coming weeks. Marcolin currently manufactures the Emilio Pucci frames as part of a licensing agreement with LVMH.
The same anonymous sources argue that the French luxury giant could possibly repatriate other brands at Marcolin, notably Celine, in order to centralize production there.
“LVMH has been making sunglasses for the Louis Vuitton line so they aren’t a stranger to the eyewear industry. Kering has made an example to all the other fashion houses that it is possible.”, said, Registered Optician and Eyewear Social Media influencer @ThroughaSpectacle., Howard K.
Industry analyst Zuzanna Pusz indicated that this would be very bad news for Safilo. Safilo currently holds licenses for several brands of LVMH (Dior, Marc Jacobs, Celine, Fendi and Givenchy). The agreement with Celine ends in 2017 and will not be renewed. The share price of Safilo lost 15% of its stock market value in the wake of these revelations.
Sources:
The Dragon Destiny collection is designed for a younger generation who has a love for life and adventure. Introducing the latest feature frames, the Grant and Sam (photo), classic shapes with an edge of fashion flare for the style conscious. Attention is paid to every last detail on these stunning frames, featuring their signature 5 barrel hinge, exposed custom core wire, and strategically placed Dragon logo detailing.
Dragon Eyewear is distributed by Marchon: www.marchon.com
ForSight VISION4, a privately held biotechnology company revolutionizing drug delivery for treatment of retinal diseases, announced today that it has been acquired by Roche Holdings Inc. The Company is the fourth venture created by the Menlo Park incubator, ForSight Labs, LLC, and was funded entirely by two of the leading venture capital firms in Silicon Valley, Morgenthaler Ventures and Versant Ventures.
The acquisition expands Roche’s exclusive access to the ForSight VISION4 PDS technology for long acting delivery of therapeutics to the eye. In 2010, ForSight VISION4, Inc. announced a Collaboration and License Agreement with Genentech, a member of the Roche Group, for exclusive rights to use ForSight VISION4’s proprietary drug delivery technology for the target VEGF-A.
“This transaction marks the successful culmination of an early and ongoing collaboration between the ForSight VISION4 team and the team at Genentech, and puts the PDS technology on a path to revolutionize retinal therapies for patients worldwide,” said K. Angela Macfarlane, President and CEO of ForSight VISION4, Inc. “We believe that Roche, a leader in ophthalmic drug development, is the ideal partner to drive the further development of the PDS.”
The PDS is a durable intravitreal implant that is placed through a scleral incision in a one-time surgical procedure. It is then refilled using a proprietary refill needle by a physician in an office setting. The ranibizumab PDS is currently in a Phase II study, the “LADDER” Study (NCT02510794) sponsored by Genentech to define the duration of drug delivery possible with the PDS technology.
ForSight VISION4 has developed the PDS to facilitate a wide array of molecules and therapeutic payloads, including delivery of small molecules that typically have a short retention time inside the eye. The acquisition by Roche provides the opportunity for the PDS technology to be applied broadly to other molecules in the Roche pipeline as an approach for extending the duration between treatments for intravitreally injected drugs.
Read the full press release available here.
UPDATE: Essilor and Delfin to create a global integrated player in the eyewear industry with the combination of Essilor and Luxottica. Click HERE for the full press release.
January 16: Merger reports confirmed by Luxottica holding company and Essilor. Read the details as published by Vision Monday …
January 15:
Reuters news is reporting tonight that a 46 Billion Euro merger of giants Essilor and Luxottica will be announced prior to stock market opening tomorrow, Monday January 16th. The deal reshapes the landscape of the industry bringing together the worlds largest optical frame company, with the leading lens and lab services company. In addition to frames and lenses, both companies have substantial market share of the traditional brick and mortar retail sector and e-retailing entities.
According to the sources, Leonardo Del Vecchio, Luxottica’s will become the largest single shareholder in the merged group and will control 31 per cent of voting rights. The two companies are approximately the same market value, making it a merger of equals, according to the reports.
The merged entity would reach revenues of nearly 16 billion euros and employ around 140,000 people world wide.
As early as March last year, Luxottica denied reports of a possible alliance with Essilor and Carl Zeiss, saying the relationship it had with the two groups was that they both were among its suppliers.
VuePoint will report further information once available.
Source: http://www.reuters.com/article/us-essilor-m-a-luxottica-group-idUSKBN14Z110
The Canadian Association of Optometrists has appointed Joelle Walker as its new CEO, effective January 2026, succeeding François Couillard after more than 40 years of leadership.
Learn More
The World Council of Optometry and Alcon have released a new video featuring eye care professionals from around the world sharing how they use the Dry Eye Wheel to support dry eye diagnosis, education, and management.
Read more
Silhouette unveils SPX Illusion 2025, featuring two new lightweight shapes— including a striking geometric design—offered in five trend-forward colors like Canary Green Havana and Smokey Blossom. A refined, featherlight way to express personal style with elegance.
Read more
EssilorLuxottica will acquire Signifeye, adding 15 Belgian clinics to its growing ophthalmology network and strengthening its integrated medical eye-care strategy.
Read more
CORE has published issue 87 of Contact Lens Update, summarizing key findings from the TFOS DEWS III dry eye reports. Expert-authored content and downloadable PDFs provide clinicians with practical guidance on diagnosis, management, and evolving best practices.
Read more
The Canadian Association of Optometrists has appointed Joelle Walker as its new CEO, effective January 2026, succeeding François Couillard after more than 40 years of leadership.
Learn More The World Council of Optometry and Alcon have released a new video featuring eye care professionals from around the world sharing how they use the Dry Eye Wheel to support dry eye diagnosis, education, and management.
Read More Silhouette unveils SPX Illusion 2025, featuring two new lightweight shapes— including a striking geometric design—offered in five trend-forward colors like Canary Green Havana and Smokey Blossom. A refined, featherlight way to express personal style with elegance.
Read More EssilorLuxottica will acquire Signifeye, adding 15 Belgian clinics to its growing ophthalmology network and strengthening its integrated medical eye-care strategy.
Read More CORE has published issue 87 of Contact Lens Update, summarizing key findings from the TFOS DEWS III dry eye reports. Expert-authored content and downloadable PDFs provide clinicians with practical guidance on diagnosis, management, and evolving best practices.
Read More
The Canadian Association of Optometrists has appointed Joelle Walker as its new CEO, effective January 2026, succeeding François Couillard after more than 40 years of leadership.
Learn More The World Council of Optometry and Alcon have released a new video featuring eye care professionals from around the world sharing how they use the Dry Eye Wheel to support dry eye diagnosis, education, and management.
Read more Silhouette unveils SPX Illusion 2025, featuring two new lightweight shapes— including a striking geometric design—offered in five trend-forward colors like Canary Green Havana and Smokey Blossom. A refined, featherlight way to express personal style with elegance.
Read more EssilorLuxottica will acquire Signifeye, adding 15 Belgian clinics to its growing ophthalmology network and strengthening its integrated medical eye-care strategy.
Read more CORE has published issue 87 of Contact Lens Update, summarizing key findings from the TFOS DEWS III dry eye reports. Expert-authored content and downloadable PDFs provide clinicians with practical guidance on diagnosis, management, and evolving best practices.
Read more The Canadian Association of Optometrists has appointed Joelle Walker as its new CEO, effective January 2026, succeeding François Couillard after more than 40 years of leadership.
Learn More The World Council of Optometry and Alcon have released a new video featuring eye care professionals from around the world sharing how they use the Dry Eye Wheel to support dry eye diagnosis, education, and management.
Read more Silhouette unveils SPX Illusion 2025, featuring two new lightweight shapes— including a striking geometric design—offered in five trend-forward colors like Canary Green Havana and Smokey Blossom. A refined, featherlight way to express personal style with elegance.
Read more EssilorLuxottica will acquire Signifeye, adding 15 Belgian clinics to its growing ophthalmology network and strengthening its integrated medical eye-care strategy.
Read more CORE has published issue 87 of Contact Lens Update, summarizing key findings from the TFOS DEWS III dry eye reports. Expert-authored content and downloadable PDFs provide clinicians with practical guidance on diagnosis, management, and evolving best practices.
Read more
